<div class="tables frame-topbot rowsep-0 colsep-0" id="tbl1">
<div class="captions"><span id="cecap60"><p id="spara110"><span class="label">Table</span>. Baseline characteristics, stratified by baseline eGFR</p></span></div>
<div class="groups"><table>
<thead>
<tr class="valign-top">
<th scope="col" colspan="2"></th>
<th scope="col" class="align-left rowsep-1" colspan="3"><strong>eGFR &lt;60 mL/min per 1·73 m<sup>2</sup></strong></th>
<th scope="col" class="align-left rowsep-1" colspan="3"><strong>eGFR ≥60 mL/min per 1·73 m<sup>2</sup></strong></th>
</tr>
<tr class="valign-top rowsep-1">
<th scope="col" colspan="2"></th>
<th scope="col" class="align-left">Canagliflozin (n=1110)</th>
<th scope="col" class="align-left">Placebo (n=929)</th>
<th scope="col" class="align-left">Total (n=2039)</th>
<th scope="col" class="align-left">Canagliflozin (n=4684)</th>
<th scope="col" class="align-left">Placebo (n=3417)</th>
<th scope="col" class="align-left">Total (n=8101)</th>
</tr>
</thead>
<tbody>
<tr class="valign-top">
<td class="align-left" colspan="2">Age (years)</td>
<td class="align-left">67·6 (7·8)</td>
<td class="align-left">67·6 (7·6)</td>
<td class="align-left">67·6 (7·7)</td>
<td class="align-left">62·1 (8·0)</td>
<td class="align-left">62·3 (8·0)</td>
<td class="align-left">62·2 (8·0)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">Sex</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Male</td>
<td class="align-left">659 (59%)</td>
<td class="align-left">527 (57%)</td>
<td class="align-left">1186 (58%)</td>
<td class="align-left">3100 (66%)</td>
<td class="align-left">2222 (65%)</td>
<td class="align-left">5322 (66%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Female</td>
<td class="align-left">451 (41%)</td>
<td class="align-left">402 (43%)</td>
<td class="align-left">853 (42%)</td>
<td class="align-left">1584 (34%)</td>
<td class="align-left">1195 (35%)</td>
<td class="align-left">2779 (34%)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">Race</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">White</td>
<td class="align-left">907 (82%)</td>
<td class="align-left">766 (82%)</td>
<td class="align-left">1673 (82%)</td>
<td class="align-left">3600 (77%)</td>
<td class="align-left">2669 (78%)</td>
<td class="align-left">6269 (77%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Asian</td>
<td class="align-left">118 (11%)</td>
<td class="align-left">98 (11%)</td>
<td class="align-left">216 (11%)</td>
<td class="align-left">659 (14%)</td>
<td class="align-left">409 (12%)</td>
<td class="align-left">1068 (13%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Black or African-American</td>
<td class="align-left">27 (2%)</td>
<td class="align-left">19 (2%)</td>
<td class="align-left">46 (2%)</td>
<td class="align-left">149 (3%)</td>
<td class="align-left">141 (4%)</td>
<td class="align-left">290 (4%)</td>
</tr>
<tr class="valign-bottom">
<td></td>
<td class="align-left">Other<a name="btbl1fn1" href="#tbl1fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">58 (5%)</td>
<td class="align-left">46 (5%)</td>
<td class="align-left">104 (5%)</td>
<td class="align-left">276 (6%)</td>
<td class="align-left">198 (6%)</td>
<td class="align-left">474 (6%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Current smoker</td>
<td class="align-left">120 (11%)</td>
<td class="align-left">106 (11%)</td>
<td class="align-left">226 (11%)</td>
<td class="align-left">900 (19%)</td>
<td class="align-left">680 (20%)</td>
<td class="align-left">1580 (20%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">History of hypertension</td>
<td class="align-left">1043 (94%)</td>
<td class="align-left">885 (95%)</td>
<td class="align-left">1928 (95%)</td>
<td class="align-left">4144 (88%)</td>
<td class="align-left">3051 (89%)</td>
<td class="align-left">7195 (89%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">History of heart failure</td>
<td class="align-left">200 (18%)</td>
<td class="align-left">164 (18%)</td>
<td class="align-left">364 (18%)</td>
<td class="align-left">603 (13%)</td>
<td class="align-left">493 (14%)</td>
<td class="align-left">1096 (14%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Duration of diabetes (years)</td>
<td class="align-left">16·1 (8·4)</td>
<td class="align-left">15·7 (8·2)</td>
<td class="align-left">15·9 (8·3)</td>
<td class="align-left">12·8 (7·4)</td>
<td class="align-left">13·1 (7·6)</td>
<td class="align-left">13·0 (7·5)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">Drug therapy</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Insulin</td>
<td class="align-left">682 (61%)</td>
<td class="align-left">562 (60%)</td>
<td class="align-left">1244 (61%)</td>
<td class="align-left">2208 (47%)</td>
<td class="align-left">1643 (48%)</td>
<td class="align-left">3851 (48%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Sulfonylurea</td>
<td class="align-left">416 (37%)</td>
<td class="align-left">342 (37%)</td>
<td class="align-left">758 (37%)</td>
<td class="align-left">2111 (45%)</td>
<td class="align-left">1490 (44%)</td>
<td class="align-left">3601 (44%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Metformin</td>
<td class="align-left">589 (53%)</td>
<td class="align-left">573 (62%)</td>
<td class="align-left">1162 (57%)</td>
<td class="align-left">3858 (82%)</td>
<td class="align-left">2805 (82%)</td>
<td class="align-left">6663 (82%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Glucagon-like peptide-1 receptor agonist</td>
<td class="align-left">40 (4%)</td>
<td class="align-left">43 (5%)</td>
<td class="align-left">83 (4%)</td>
<td class="align-left">182 (4%)</td>
<td class="align-left">142 (4%)</td>
<td class="align-left">324 (4%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Dipeptidyl peptidase-4 inhibitor</td>
<td class="align-left">131 (12%)</td>
<td class="align-left">152 (16%)</td>
<td class="align-left">283 (14%)</td>
<td class="align-left">566 (12%)</td>
<td class="align-left">412 (12%)</td>
<td class="align-left">978 (12%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Statin</td>
<td class="align-left">876 (79%)</td>
<td class="align-left">714 (77%)</td>
<td class="align-left">1590 (78%)</td>
<td class="align-left">3454 (74%)</td>
<td class="align-left">2556 (75%)</td>
<td class="align-left">6010 (74%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Antithrombotic</td>
<td class="align-left">889 (80%)</td>
<td class="align-left">730 (79%)</td>
<td class="align-left">1619 (79%)</td>
<td class="align-left">3347 (71%)</td>
<td class="align-left">2505 (73%)</td>
<td class="align-left">5852 (72%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Renin–angiotensin system inhibitor</td>
<td class="align-left">908 (82%)</td>
<td class="align-left">747 (80%)</td>
<td class="align-left">1655 (81%)</td>
<td class="align-left">3736 (80%)</td>
<td class="align-left">2723 (80%)</td>
<td class="align-left">6459 (80%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">β blocker</td>
<td class="align-left">674 (61%)</td>
<td class="align-left">601 (65%)</td>
<td class="align-left">1275 (63%)</td>
<td class="align-left">2365 (50%)</td>
<td class="align-left">1780 (52%)</td>
<td class="align-left">4145 (51%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Diuretic</td>
<td class="align-left">662 (60%)</td>
<td class="align-left">560 (60%)</td>
<td class="align-left">1222 (60%)</td>
<td class="align-left">1874 (40%)</td>
<td class="align-left">1394 (41%)</td>
<td class="align-left">3268 (40%)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">Microvascular disease history</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Retinopathy</td>
<td class="align-left">286 (26%)</td>
<td class="align-left">269 (29%)</td>
<td class="align-left">555 (27%)</td>
<td class="align-left">917 (20%)</td>
<td class="align-left">657 (19%)</td>
<td class="align-left">1574 (19%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Nephropathy</td>
<td class="align-left">356 (32%)</td>
<td class="align-left">293 (32%)</td>
<td class="align-left">649 (32%)</td>
<td class="align-left">638 (14%)</td>
<td class="align-left">487 (14%)</td>
<td class="align-left">1125 (14%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Neuropathy</td>
<td class="align-left">394 (35%)</td>
<td class="align-left">300 (32%)</td>
<td class="align-left">694 (34%)</td>
<td class="align-left">1393 (30%)</td>
<td class="align-left">1023 (30%)</td>
<td class="align-left">2416 (30%)</td>
</tr>
<tr class="valign-bottom"><td class="align-left" colspan="8">Atherosclerotic vascular disease history<a name="btbl1fn2" href="#tbl1fn2" class="workspace-trigger"><sup>†</sup></a>
</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Coronary</td>
<td class="align-left">621 (56%)</td>
<td class="align-left">515 (55%)</td>
<td class="align-left">1136 (56%)</td>
<td class="align-left">2398 (51%)</td>
<td class="align-left">1746 (51%)</td>
<td class="align-left">4144 (51%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Cerebrovascular</td>
<td class="align-left">250 (23%)</td>
<td class="align-left">207 (22%)</td>
<td class="align-left">457 (22%)</td>
<td class="align-left">863 (18%)</td>
<td class="align-left">636 (19%)</td>
<td class="align-left">1499 (19%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Peripheral</td>
<td class="align-left">289 (26%)</td>
<td class="align-left">216 (23%)</td>
<td class="align-left">505 (25%)</td>
<td class="align-left">887 (19%)</td>
<td class="align-left">721 (21%)</td>
<td class="align-left">1608 (20%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Any</td>
<td class="align-left">816 (74%)</td>
<td class="align-left">681 (73%)</td>
<td class="align-left">1497 (73%)</td>
<td class="align-left">3160 (67%)</td>
<td class="align-left">2368 (69%)</td>
<td class="align-left">5528 (68%)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">Cardiovascular disease history<a name="btbl1fn3" href="#tbl1fn3" class="workspace-trigger"><sup>‡</sup></a>
</td>
<td class="align-left">799 (72%)</td>
<td class="align-left">661 (71%)</td>
<td class="align-left">1460 (72%)</td>
<td class="align-left">2957 (63%)</td>
<td class="align-left">2238 (65%)</td>
<td class="align-left">5195 (64%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">History of amputation</td>
<td class="align-left">47 (4%)</td>
<td class="align-left">37 (4%)</td>
<td class="align-left">84 (4%)</td>
<td class="align-left">89 (2%)</td>
<td class="align-left">65 (2%)</td>
<td class="align-left">154 (2%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">BMI (kg/m<sup>2</sup>)</td>
<td class="align-left">32·1 (5·9)</td>
<td class="align-left">32·5 (6·2)</td>
<td class="align-left">32·3 (6·0)</td>
<td class="align-left">31·9 (5·9)</td>
<td class="align-left">31·8 (5·9)</td>
<td class="align-left">31·9 (5·9)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Systolic blood pressure (mm Hg)</td>
<td class="align-left">137·3 (16·9)</td>
<td class="align-left">137·7 (16·1)</td>
<td class="align-left">137·5 (16·6)</td>
<td class="align-left">136·2 (15·5)</td>
<td class="align-left">136·7 (15·7)</td>
<td class="align-left">136·4 (15·6)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Diastolic blood pressure (mm Hg)</td>
<td class="align-left">75·6 (10·1)</td>
<td class="align-left">75·4 (10·2)</td>
<td class="align-left">75·5 (10·1)</td>
<td class="align-left">78·1 (9·5)</td>
<td class="align-left">78·4 (9·5)</td>
<td class="align-left">78·2 (9·5)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">HbA<sub>1c</sub>
</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">%</td>
<td class="align-left">8·3% (1·0)</td>
<td class="align-left">8·3% (0·9)</td>
<td class="align-left">8·3% (0·9)</td>
<td class="align-left">8·2% (0·9)</td>
<td class="align-left">8·2% (0·9)</td>
<td class="align-left">8·2% (0·9)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mmol/mol</td>
<td class="align-left">67 (10·9)</td>
<td class="align-left">67 (9·8)</td>
<td class="align-left">67 (9·8)</td>
<td class="align-left">66 (9·8)</td>
<td class="align-left">66 (9·8)</td>
<td class="align-left">66 (9·8)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">Total cholesterol</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mg/dL</td>
<td class="align-left">170·2 (43·6)</td>
<td class="align-left">168·1 (44·5)</td>
<td class="align-left">169·2 (44·0)</td>
<td class="align-left">167·9 (44·3)</td>
<td class="align-left">169·1 (45·3)</td>
<td class="align-left">168·4 (44·7)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mmol/L</td>
<td class="align-left">4·4 (1·1)</td>
<td class="align-left">4·4 (1·2)</td>
<td class="align-left">4·4 (1·1)</td>
<td class="align-left">4·3 (1·1)</td>
<td class="align-left">4·4 (1·2)</td>
<td class="align-left">4·4 (1·2)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">Triglycerides</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mg/dL</td>
<td class="align-left">191·1 (122·0)</td>
<td class="align-left">194·3 (117·5)</td>
<td class="align-left">192·6 (120·0)</td>
<td class="align-left">176·5 (117·2)</td>
<td class="align-left">176·8 (139·1)</td>
<td class="align-left">176·7 (126·9)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mmol/L</td>
<td class="align-left">2·2 (1·4)</td>
<td class="align-left">2·2 (1·3)</td>
<td class="align-left">2·2 (1·4)</td>
<td class="align-left">2·0 (1·3)</td>
<td class="align-left">2·0 (1·6)</td>
<td class="align-left">2·0 (1·4)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">HDL cholesterol</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mg/dL</td>
<td class="align-left">45·3 (13·0)</td>
<td class="align-left">44·2 (11·6)</td>
<td class="align-left">44·8 (12·4)</td>
<td class="align-left">45·6 (12·3)</td>
<td class="align-left">45·8 (11·8)</td>
<td class="align-left">45·7 (12·1)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mmol/L</td>
<td class="align-left">1·2 (0·3)</td>
<td class="align-left">1·1 (0·3)</td>
<td class="align-left">1·2 (0·3)</td>
<td class="align-left">1·2 (0·3)</td>
<td class="align-left">1·2 (0·3)</td>
<td class="align-left">1·2 (0·3)</td>
</tr>
<tr class="valign-top"><td class="align-left" colspan="8">LDL cholesterol</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mg/dL</td>
<td class="align-left">88·8 (36·1)</td>
<td class="align-left">86·8 (36·4)</td>
<td class="align-left">87·9 (36·2)</td>
<td class="align-left">88·6 (36·1)</td>
<td class="align-left">89·9 (36·1)</td>
<td class="align-left">89·2 (36·1)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mmol/L</td>
<td class="align-left">2·3 (0·9)</td>
<td class="align-left">2·2 (0·9)</td>
<td class="align-left">2·3 (0·9)</td>
<td class="align-left">2·3 (0·9)</td>
<td class="align-left">2·3 (0·9)</td>
<td class="align-left">2·3 (0·9)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Ratio of LDL to HDL cholesterol</td>
<td class="align-left">2·1 (1·0)</td>
<td class="align-left">2·0 (0·9)</td>
<td class="align-left">2·1 (0·9)</td>
<td class="align-left">2·0 (0·9)</td>
<td class="align-left">2·0 (0·9)</td>
<td class="align-left">2·0 (0·9)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">eGFR (mL/min per 1·73 m<sup>2</sup>)</td>
<td class="align-left">49·2 (7·8)</td>
<td class="align-left">49·0 (8·3)</td>
<td class="align-left">49·1 (8·0)</td>
<td class="align-left">83·2 (16·5)</td>
<td class="align-left">83·6 (16·7)</td>
<td class="align-left">83·4 (16·6)</td>
</tr>
<tr class="valign-bottom"><td class="align-left" colspan="8">Urinary albumin-to-creatinine ratio<a name="btbl1fn4" href="#tbl1fn4" class="workspace-trigger"><sup>§</sup></a>
</td></tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mg/g</td>
<td class="align-left">21·5 (7·5–132·7)</td>
<td class="align-left">21·7 (7·9–105·5)</td>
<td class="align-left">21·6 (7·7–117·8)</td>
<td class="align-left">11·5 (6·6–33·0)</td>
<td class="align-left">11·1 (6·4–33·0)</td>
<td class="align-left">11·3 (6·5–33·0)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">mg/mmol</td>
<td class="align-left">2·4 (0·9–15·0)</td>
<td class="align-left">2·4 (0·9–11·9)</td>
<td class="align-left">2·4 (0·9–13·3)</td>
<td class="align-left">1·3 (0·7–3·7)</td>
<td class="align-left">1·3 (0·7–3·7)</td>
<td class="align-left">1·3 (0·7–3·7)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">Normoalbuminuria<a name="btbl1fn4" href="#tbl1fn4" class="workspace-trigger"><sup>§</sup></a>
</td>
<td class="align-left">610 (56%)</td>
<td class="align-left">519 (57%)</td>
<td class="align-left">1129 (56%)</td>
<td class="align-left">3401 (73%)</td>
<td class="align-left">2475 (73%)</td>
<td class="align-left">5876 (73%)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">Microalbuminuria or macroalbuminuria<a name="btbl1fn4" href="#tbl1fn4" class="workspace-trigger"><sup>§</sup></a>
</td>
<td class="align-left">489 (44%)</td>
<td class="align-left">398 (43%)</td>
<td class="align-left">887 (44%)</td>
<td class="align-left">1239 (27%)</td>
<td class="align-left">900 (27%)</td>
<td class="align-left">2139 (27%)</td>
</tr>
</tbody>
</table></div>
<p class="legend"></p>
<p id="spara120">Data are n (%), mean (SD), or median (IQR). eGFR=estimated glomerular filtration rate.</p>
<dl class="footnotes">
<dt id="tbl1fn1">*</dt>
<dd><p id="cenpara10">Includes native American or Alaskan, Hawaiian or other Pacific Islander, multiple races, other races, and unknown race.</p></dd>
<dt id="tbl1fn2">†</dt>
<dd><p id="cenpara20">Some participants had more than one type of atherosclerotic disease.</p></dd>
<dt id="tbl1fn3">‡</dt>
<dd><p id="cenpara30">As defined in the protocol.</p></dd>
<dt id="tbl1fn4">§</dt>
<dd><p id="cenpara40">Based
 on 1099 participants receiving canagliflozin and 917 participants 
receiving placebo, of 2016 total participants in the eGFR &lt;60 mL/min 
per 1·73 m<sup>2</sup> subgroup and 4640 participants receiving 
canagliflozin and 3375 participants receiving placebo, of 8015 total 
participants in the eGFR ≥60 mL/min per 1·73 m<sup>2</sup> subgroup.</p></dd>
</dl>
</div>